книги / 761

: WHO unpublished data, OECD Health Statistics 2018.

StatLink http://dx.doi.org/10.1787/888933868785

: WHO unpublished data, OECD Health Statistics 2018.

StatLink http://dx.doi.org/10.1787/888933868804

-(Chan , 2017).( : , , ,, ) ,( , , ,) , , - . ., , , B .

,.

B 1982 ,95%. 2015 B887,000 , () (WHO, 2018e). 2007 170B ( ). B 3 B(WHO, 2017f). 1990~2014B7 , 3,700(Wiesen , 2016).

7.1 7.2 2016() . 2016 1 , 89%

86% . ., 2016 43 .

7.3 1 B .80% ,.

. 2007 B6% 40% , 201688% 76% ..

. WHO 2016

(adverse events following immunisation, AEFI) 184 107 10 10 . , AEFI 75% 49% AEFI(Global Vaccine Action Plan, 2017).

1 21 ..

. ( :MR) ,

. .

2016

34.7% 25.2% (WHO, 2018a). ,, . (AMI) 10 . 1990 . AMI(Gil , 1999),6 (O’Rourke , 2010, Wardlaw , 2014). (Seenan , 2007), (Eagle , 2005).

AMI .. AMI 30, (4%)

(4.7%) ( 7.4). 11.7%. 30 ,, , AMI.

(3.1%) (3.9%) , 7.7%

( 7.5). , .

(11.2%) (17.1%) , 23.6%( 7.6). .

환자나30 . . .

AMI, , 30 ( ). ,, , . .

.(45 )

,.

H .

20(WHO, 2018)., , ,,

(World Cancer Research Fund, 2018, Gonzales-Jimenez , 2014).

15. 95% (human papilloma virus, HPV) .HPV DNA (premalignant lesions)(WHO, 2014f). 1(Arrossi , 2017).

OECD , (OECD, 2017).35 (WHO, 2018a). ,, . ,(Arnold , 2017)., S 2 (Centers for Disease Control and Prevention, 2016).

5 (net survival) .(89.5%) (89.4%) 5 , ,5

70% ( 7.7).

(77.3%) (71.4%) 5(53.9%) (57.1%) ( 7.8).. (10 34.5 37.8 )

5.5 5.3 (Ferlay , 2013).

(71.8%) (70.7%) 5(38.9%) ( 7.9). ,(71.1%) (71.0%)

(30%) .

5 (net survival)

5. . 2000~20042014

5(cohort approach) . 2010~2014

5(period approach)

5. (International Cancer Survival Standard, ICSS)

.

CONCORD

, ,

(Allemani , 2015). CONCORD

.

, , , , ,100%

( ) .5 .

H .